MicroRNA-21 As Therapeutic Target in Cancer and Cardiovascular Disease
Overview
Authors
Affiliations
MicroRNAs (miRNAs) are a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of miRNAs has been described in various disease states including cancer and cardiac disease. A particular miRNA that was consistently reported to be upregulated in both cancer and various forms of cardiovascular diseases is miR-21. MiR-21 exerts oncogenic activity and therefore is considered as an oncomir. In the cardiovascular system miR-21 is enriched in fibroblasts and contributes to the development of fibrosis and heart failure. MiR-21 therefore emerges as an interesting candidate for the development of therapeutic strategies against many forms of cancer as well as heart diseases. Indeed, treatment with anti-miR-21 oligonucleotides reduced breast cancer growth. Inhibition of miR-21 by synthetic miRNA antagonists (antagomirs) improved heart function in a cardiac disease model. The same beneficial effects were observed in miR-21 knockout mice subjected to pressure-overload of the left ventricle underlining the key role of miR-21 as a therapeutic target. We here overview the current patent situation about the therapeutic use of miR-21 modulation in cancer and cardiovascular disease.
You J, Chen Y, Hsieh C, Chen S, Lin T, Shih J Cancers (Basel). 2023; 15(19).
PMID: 37835505 PMC: 10571555. DOI: 10.3390/cancers15194812.
Desantis V, Potenza M, Sgarra L, Nacci C, Scaringella A, Cicco S Int J Mol Sci. 2023; 24(6).
PMID: 36982382 PMC: 10049145. DOI: 10.3390/ijms24065307.
Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer.
Petrouskova P, Hudakova N, Maloveska M, Humenik F, Cizkova D Life (Basel). 2022; 12(4).
PMID: 35455015 PMC: 9032658. DOI: 10.3390/life12040524.
Chang W, Wu C, Lin Y, Shih J, Chen Z, Wu S Cells. 2022; 11(3).
PMID: 35159373 PMC: 8834169. DOI: 10.3390/cells11030564.
miR-21 in Human Cardiomyopathies.
Surina S, Fontanella R, Scisciola L, Marfella R, Paolisso G, Barbieri M Front Cardiovasc Med. 2021; 8:767064.
PMID: 34778418 PMC: 8578278. DOI: 10.3389/fcvm.2021.767064.